1
|
Fang C, Ouyang W, Zeng Y, Pei Q, Xia Y, Luo S, Chen M. CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response. Front Pharmacol 2022; 13:943200. [PMID: 35873555 PMCID: PMC9301121 DOI: 10.3389/fphar.2022.943200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Accepted: 06/20/2022] [Indexed: 11/20/2022] Open
Abstract
Background: Dexmedetomidine is a commonly used clinical sedative; however, the drug response varies among individuals. Thus, the purpose of this study was to explore the association between dexmedetomidine response and gene polymorphisms related to drug-metabolizing enzymes and drug response (CYP2A6, UGT2B10, UGT1A4, ADRA2A, ADRA2B, ADRA2C, GABRA1, GABRB2, and GLRA1). Methods: This study was a prospective cohort study. A total of 194 female patients aged 18–60 years, American Society of Anesthesiologists (ASA) score I-II, who underwent laparoscopy at the Third Xiangya Hospital of Central South University, were included. The sedative effect was assessed every 2 min using the Ramsay score, and the patient’s heart rate decrease within 20 min was recorded. Peripheral blood was collected from each participant to identify genetic variants in the candidate genes of metabolic and drug effects using the Sequenom MassARRAY® platform. Furthermore, additional peripheral blood samples were collected from the first 99 participants at multiple time points after dexmedetomidine infusion to perform dexmedetomidine pharmacokinetic analysis by Phoenix® WinNonlin 7.0 software. Results: Carriers of the minor allele (C) of CYP2A6 rs28399433 had lower metabolic enzyme efficiency and higher plasma concentrations of dexmedetomidine. In addition, the participants were divided into dexmedetomidine sensitive or dexmedetomidine tolerant groups based on whether they had a Ramsay score of at least four within 20 min, and CYP2A6 rs28399433 was identified to have a significant influence on the dexmedetomidine sedation sensitivity by logistic regression with Plink software [p = 0.003, OR (95% CI): 0.27 (0.11–0.65)]. C allele carriers were more sensitive to the sedative effects of dexmedetomidine than A allele carriers. GABRA2 rs279847 polymorphism was significantly associated with the degree of the heart rate decrease. In particular, individuals with the GG genotype had a 4-fold higher risk of heart rate abnormality than carriers of the T allele (OR = 4.32, 95% CI: 1.96–9.50, p = 0.00027). Conclusion:CYP2A6 rs28399433 polymorphism affects the metabolic rate of dexmedetomidine and is associated with susceptibility to the sedative effects of dexmedetomidine; GABRA2 rs279847 polymorphism is significantly associated with the degree of the heart rate decrease.
Collapse
Affiliation(s)
- Chao Fang
- Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China
- Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - Wen Ouyang
- Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China
| | - Youjie Zeng
- Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China
| | - Qi Pei
- Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha, China
| | - Yuhao Xia
- Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China
| | - Siwan Luo
- Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China
| | - Minghua Chen
- Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China
- *Correspondence: Minghua Chen,
| |
Collapse
|
2
|
Wang G, Xiao B, Deng J, Gong L, Li Y, Li J, Zhong Y. The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy. Front Pharmacol 2022; 13:791922. [PMID: 35185562 PMCID: PMC8847594 DOI: 10.3389/fphar.2022.791922] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 01/05/2022] [Indexed: 12/15/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) has become a new public health crisis threatening the world. Dysregulated immune responses are the most striking pathophysiological features of patients with severe COVID-19, which can result in multiple-organ failure and death. The cytochrome P450 (CYP) system is the most important drug metabolizing enzyme family, which plays a significant role in the metabolism of endogenous or exogenous substances. Endogenous CYPs participate in the biosynthesis or catabolism of endogenous substances, including steroids, vitamins, eicosanoids, and fatty acids, whilst xenobiotic CYPs are associated with the metabolism of environmental toxins, drugs, and carcinogens. CYP expression and activity are greatly affected by immune response. However, changes in CYP expression and/or function in COVID-19 and their impact on COVID-19 pathophysiology and the metabolism of therapeutic agents in COVID-19, remain unclear. In this analysis, we review current evidence predominantly in the following areas: firstly, the possible changes in CYP expression and/or function in COVID-19; secondly, the effects of CYPs on the metabolism of arachidonic acid, vitamins, and steroid hormones in COVID-19; and thirdly, the effects of CYPs on the metabolism of therapeutic COVID-19 drugs.
Collapse
Affiliation(s)
- Guyi Wang
- Department of Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Bing Xiao
- Department of Emergency, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Jiayi Deng
- Department of Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Linmei Gong
- Department of Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Yi Li
- Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Jinxiu Li
- Department of Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Yanjun Zhong
- Department of Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
| |
Collapse
|
3
|
Dexmedetomidine Clearance Decreases with Increasing Drug Exposure: Implications for Current Dosing Regimens and Target-controlled Infusion Models Assuming Linear Pharmacokinetics. Anesthesiology 2021; 136:279-292. [PMID: 34851425 DOI: 10.1097/aln.0000000000004049] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Numerous pharmacokinetic models have been published aiming at more accurate and safer dosing of dexmedetomidine. The vast majority of the developed models underpredict the measured plasma concentrations with respect to the target concentration, especially at plasma concentrations higher than those used in the original studies. The aim of this article was to develop a dexmedetomidine pharmacokinetic model in healthy adults emphasizing linear versus nonlinear kinetics. METHODS The data of two previously published clinical trials with stepwise increasing dexmedetomidine target-controlled infusion were pooled to build a pharmacokinetic model using the NONMEM software package (ICON Development Solutions, USA). Data from 48 healthy subjects, included in a stratified manner, were utilized to build the model. RESULTS A three-compartment mamillary model with nonlinear elimination from the central compartment was superior to a model assuming linear pharmacokinetics. Covariates included in the final model were age, sex, and total body weight. Cardiac output did not explain between-subject or within-subject variability in dexmedetomidine clearance. The results of a simulation study based on the final model showed that at concentrations up to 2 ng · ml-1, the predicted dexmedetomidine plasma concentrations were similar between the currently available Hannivoort model assuming linear pharmacokinetics and the nonlinear model developed in this study. At higher simulated plasma concentrations, exposure increased nonlinearly with target concentration due to the decreasing dexmedetomidine clearance with increasing plasma concentrations. Simulations also show that currently approved dosing regimens in the intensive care unit may potentially lead to higher-than-expected dexmedetomidine plasma concentrations. CONCLUSIONS This study developed a nonlinear three-compartment pharmacokinetic model that accurately described dexmedetomidine plasma concentrations. Dexmedetomidine may be safely administered up to target-controlled infusion targets under 2 ng · ml-1 using the Hannivoort model, which assumed linear pharmacokinetics. Consideration should be taken during long-term administration and during an initial loading dose when following the dosing strategies of the current guidelines. EDITOR’S PERSPECTIVE
Collapse
|
4
|
Lee CF, Cheng CH, Hung HC, Lee JC, Wang YC, Wu TH, Wu TJ, Chou HS, Chan KM, Lee WC. Sedative and Immunosuppressive Effects of Dexmedetomidine in Transplantation. Pharmaceuticals (Basel) 2021; 14:825. [PMID: 34451922 PMCID: PMC8400267 DOI: 10.3390/ph14080825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 08/19/2021] [Accepted: 08/19/2021] [Indexed: 11/17/2022] Open
Abstract
Dexmedetomidine, an α2-adrenergic receptor agonist, is used as an anti-anxiety medication. It exerts a cholinergic effect, thereby reducing the release of tumor necrosis factor alpha (TNF-α). We hypothesized that the use of dexmedetomidine as a sedative agent in transplantation would also protect allografts. We examined our patients who underwent living donor liver transplantation. Subsequently, we generated a series of mouse models to investigate the effect of dexmedetomidine on sedation-based tolerance post transplantation. A total of 49 liver recipients were enrolled in this study, of which 23 (47%) were administered dexmedetomidine through 24 h infusion on postoperative day 1. A trend toward the improvement of hepatocyte injury along with better liver function was observed in the dexmedetomidine-treated group during the first postoperative week. In animal models, dexmedetomidine inhibited the proliferation of CD4+ and CD8+ T cells and TNF-α production in a dose-dependent manner. We used dexmedetomidine to treat skin-transplanted mice and observed a significantly prolonged graft survival in mice that were administered a higher dose of dexmedetomidine. Our results revealed that dexmedetomidine exerts a dual effect of sedation and immunosuppression. This light-sedation approach will not only make patients calmer in the intensive care unit but also protect allografts from injury.
Collapse
Affiliation(s)
- Chen-Fang Lee
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
- College of Medicine, Chang-Gung University, Taoyuan City 333, Taiwan
| | - Chih-Hsien Cheng
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| | - Hao-Chien Hung
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| | - Jin-Chiao Lee
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| | - Yu-Chiao Wang
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| | - Tsung-Han Wu
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| | - Ting-Jung Wu
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| | - Hong-Shiue Chou
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| | - Kun-Ming Chan
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| | - Wei-Chen Lee
- Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan; (C.-H.C.); (H.-C.H.); (J.-C.L.); (Y.-C.W.); (T.-H.W.); (T.-J.W.); (H.-S.C.); (K.-M.C.); (W.-C.L.)
| |
Collapse
|
5
|
Matsumoto S, Uehara S, Kamimura H, Ikeda H, Maeda S, Hattori M, Nishiwaki M, Kato K, Yamazaki H. Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19. Xenobiotica 2021; 51:479-493. [PMID: 33455494 DOI: 10.1080/00498254.2020.1871113] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Common marmosets (Callithrix jacchus) are small non-human primates that genetically lack cytochrome P450 2C9 (CYP2C9). Polymorphic marmoset CYP2C19 compensates by mediating oxidations of typical human CYP2C9/19 substrates.Twenty-four probe substrates were intravenously administered in combinations to marmosets assigned to extensive or poor metaboliser (PM) groups by CYP2C19 genotyping. Eliminations from plasma of cilomilast, phenytoin, repaglinide, tolbutamide, and S-warfarin in the CYP2C19 PM group were significantly slow; these drugs are known substrates of human CYP2C8/9/19.Human total clearance values and volumes of distribution of the 24 test compounds were extrapolated using single-species allometric scaling with experimental data from marmosets and found to be mostly comparable with the reported values.Human total clearance values and volumes of distribution of 15 of the 24 test compounds similarly extrapolated using reported data sets from cynomolgus or rhesus monkeys were comparable to the present predicted results, especially to those based on data from PM marmosets.These results suggest that single-species allometric scaling using marmosets, being small, has advantages over multiple-species-based allometry and could be applicable for pharmacokinetic predictions at the discovery stage of drug development.
Collapse
Affiliation(s)
- Shogo Matsumoto
- Pharmaceutical Research Labs., Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Shotaro Uehara
- Central Institute for Experimental Animals, Kawasaki, Japan.,Pharmaceutical University, Machida, Tokyo, Japan
| | - Hidetaka Kamimura
- Central Institute for Experimental Animals, Kawasaki, Japan.,Business Promotion Dept., CLEA Japan, Inc., Tokyo, Japan
| | - Hiroshi Ikeda
- Tokyo Animal & Diet Dept., CLEA Japan, Inc., Tokyo, Japan
| | - Satoshi Maeda
- Yaotsu Breeding Center, CLEA Japan, Inc., Gifu, Japan
| | | | - Megumi Nishiwaki
- Fuji Technical Service Center, CLEA Japan, Inc.., Shizuoka, Japan
| | - Kazuhiko Kato
- Pharmaceutical Research Labs., Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | | |
Collapse
|
6
|
Guan Y, Li B, Wei W, Wang S, Yuen V, Liu Y, Ao Z, Zhou S, Tian H, Huang M, Song X, Zhong G. Quantitative ultra‐high‐performance liquid chromatography–tandem mass spectrometry for determination of dexmedetomidine in pediatric plasma samples: Correlation with genetic polymorphisms. Biomed Chromatogr 2019; 33:e4683. [DOI: 10.1002/bmc.4683] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 07/04/2019] [Accepted: 08/04/2019] [Indexed: 11/07/2022]
Affiliation(s)
- Yanping Guan
- Institute of Clinical Pharmacology, School of Pharmaceutical SciencesSun Yat‐Sen University Guangzhou China
- Department of Pharmacy, Sun Yat‐Sen Memorial HospitalSun Yat‐Sen University Guangzhou China
| | - Bilian Li
- Department of AnaesthesiologyGuangzhou Women and Children's Medical Center and Guangzhou Medical University Guangzhou China
| | - Wei Wei
- Department of AnaesthesiologyGuangzhou Women and Children's Medical Center and Guangzhou Medical University Guangzhou China
| | - Siyi Wang
- Institute of Clinical Pharmacology, School of Pharmaceutical SciencesSun Yat‐Sen University Guangzhou China
| | - Vivian‐min Yuen
- Department of AnaesthesiologyHong Kong Children's Hospital Hong Kong China
| | - Yao Liu
- Institute of Clinical Pharmacology, School of Pharmaceutical SciencesSun Yat‐Sen University Guangzhou China
| | - Zheng Ao
- Department of AnaesthesiologyGuangzhou Women and Children's Medical Center and Guangzhou Medical University Guangzhou China
| | - Shan Zhou
- Institute of Clinical Pharmacology, School of Pharmaceutical SciencesSun Yat‐Sen University Guangzhou China
| | - Hang Tian
- Department of AnaesthesiologyGuangzhou Women and Children's Medical Center and Guangzhou Medical University Guangzhou China
| | - Min Huang
- Institute of Clinical Pharmacology, School of Pharmaceutical SciencesSun Yat‐Sen University Guangzhou China
| | - Xingrong Song
- Department of AnaesthesiologyGuangzhou Women and Children's Medical Center and Guangzhou Medical University Guangzhou China
| | - Guoping Zhong
- Institute of Clinical Pharmacology, School of Pharmaceutical SciencesSun Yat‐Sen University Guangzhou China
| |
Collapse
|